Developing a new medication to help people quit smoking
Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction
This study is testing a new medication that might help adults who want to quit smoking by making it easier to resist cravings and stay smoke-free.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10466858 on NIH RePORTER |
What this research studies
This research focuses on creating a medication that targets specific brain receptors to help individuals overcome nicotine addiction. The approach involves using a compound called SBI-0069330, which enhances the function of metabotropic glutamate receptor subtype 2 (mGlu2) to reduce the reinforcing effects of nicotine and prevent relapse. The study will assess the safety and effectiveness of this medication in adults who struggle with smoking addiction, aiming to improve their chances of quitting. Participants may benefit from a novel treatment that could make it easier to stop smoking and maintain abstinence.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are struggling with nicotine addiction.
Not a fit: Patients who do not smoke or are not seeking to quit smoking may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for individuals trying to quit smoking.
How similar studies have performed: Previous research has shown promise in using mGlu2 positive allosteric modulators for treating substance use disorders, indicating potential success for this approach.
Where this research is happening
La Jolla, United States
- Sanford Burnham Prebys Medical Discovery Institute — La Jolla, United States (Active)
Researchers
- Principal investigator: Cosford, Nicholas David — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Cosford, Nicholas David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.